Dashboard/ALIVUS

ALIVUS

FAIRLY_VALUED

Alivus Life Sciences Limited

Healthcare · NSE

↓ 14.7% vs fair value

52W Low

₹819

+26.9% from low

52W High

₹1,155

-10.1% from high

News sentiment

10 bull13 neu0 bear

✦

Analyst Note

2d ago

Alivus Life Sciences Limited is fairly valued, with a margin of safety of -14.3% compared to its fair value of ₹905.74. The stock's current trading price of ₹1,039 is 9.8% above its 52-week low. Key strengths include a high return on equity of 18.4% and a strong free cash flow conversion rate of 225%. Sentiment has turned bearish over the last week despite a bullish 30-day trend. This stock suits long-term investors seeking stable growth.

8 articles

Alivus Life Sciences Ltd Technical Momentum Shifts Signal Bullish Outlook - Markets Mojo

Google News: ALIVUS·13d ago

▲ BULLISH

Alivus Life Sciences Schedules Q4 FY2025-26 Earnings Call for May 15, 2026 - scanx.trade

Google News: ALIVUS·14d ago

– NEUTRAL

Alivus Life Sciences Schedules Board Meeting on May 14, 2026 to Approve FY26 Audited Results and Consider Dividend - scanx.trade

Google News: ALIVUS·15d ago

– NEUTRAL

Alivus Life Sciences Ltd Sees Bullish Momentum Shift Amid Strong Technical Signals - Markets Mojo

Google News: ALIVUS·15d ago

Alivus Life Sciences Ltd Upgraded to Buy on Strong Technical and Financial Performance - Markets Mojo

Google News: ALIVUS·15d ago

▲ BULLISH

Alivus Life Sciences Downgraded to Hold Amid Mixed Technical and Valuation Signals - Markets Mojo

Google News: ALIVUS·23d ago

Alivus Life Sciences Ltd Sees Technical Momentum Shift Amid Mixed Market Signals - Markets Mojo

Google News: ALIVUS·23d ago

– NEUTRAL

Alivus Life Sciences Ltd is Rated Buy - Markets Mojo

Google News: ALIVUS·28d ago

▲ BULLISH

Valuation Gauge

FAIRLY_VALUED-14.7% Margin of Safety

OVERVALUEDFAIRLY VALUEDUNDERVALUED

Current Price

₹1,039

Fair Value

₹906

Fair Value Analysis

₹906

Based on earnings growth potential for Healthcare sector companies

Low confidence

Growth Valuation

100% weight

₹906

Price vs Market

ALIVUS

Nifty 50

Technical Pulse

Plain English — no jargon

RSI 50Neutral

52-week range-8% from high

L 851.15H 1,148.4

20-day avg₹1,068▼ 1.1%

50-day avg₹1,022▲ 3.4%

📍

Price PositionNeutral

Not enough price history to assess trend.

💪

Momentum (RSI)Neutral

RSI is 50 — neutral momentum, neither overbought nor oversold.

📈

Short-term TrendNeutral

Below 20-day but above 50-day average — short-term weakness but medium trend intact.

→Combined Verdict

Fairly valued with neutral momentum. Hold if you own it. No urgent reason to buy or sell.

Shareholding Pattern

Stock Health Score

B+

Financially Healthy

7.4 / 10

Profitability

10/10

ROE of 18.4% is above the Healthcare sector benchmark of 15% — strong returns

Debt & Leverage

10/10

D/E ratio of 0.0x is well within the Healthcare sector norm of 0.8x — strong balance sheet

Valuation vs Peers

10/10

P/E of 28.2x trades at a 82% discount to Healthcare sector median (160x) — attractively valued

Cash Flow

6/10

FCF margin of 9.6% — healthy cash generation (₹225 Cr)

Earnings Growth

4/10

5yr EPS CAGR of 5.1% is well below Healthcare sector average of 18.7%

Dividend

4/10

Dividend yield of 0.5% is symbolic — low but positive

Company Health Timeline

10-year financial health at a glance

FY19

FY20

FY21

Revenue Growthⓘ

OPM %ⓘ

Net Profitⓘ

Free Cash Flowⓘ

ROE %ⓘ

ROCE %ⓘ

Debt / Equityⓘ

Interest Cov.ⓘ

Health Score

100

Strong

Moderate

Weak

Poor

No data

Sentiment Trend — Last 30 Days

Historical Returns

Key Ratios & Growth

Revenue Growth (YoY)

-8.8%

Year-on-year revenue change

Profit Growth (YoY)

-12.2%

Year-on-year PAT change

Key Financials

EPS (TTM)

₹36.6

P/E Ratio

28.3x

P/B Ratio

4.2x

ROE

18.4%

ROCE

22.3%

Debt / Equity

0.02x

Beta

—

Div Yield

0.5%

FCF (Cr)

₹225 Cr

Revenue (Cr)

₹2,340 Cr

EPS Growth 5Y

5.1%

Mkt Cap (Cr)

₹12,821 Cr

52W High

₹1,155.2

52W Low

₹819

Book Value/Share

₹245.8

Financial History

Period	Revenue	Op Profit	OPM%	PAT	EPS
2021-03-31	₹1.9K Cr	₹591 Cr	31.0%	₹352 Cr	₹358.74
2020-03-31	₹1.5K Cr	₹472 Cr	31.0%	₹313 Cr	₹1597.37
2019-03-31	₹886 Cr	₹248 Cr	28.0%	₹196 Cr	₹997.86

Compounded Growth Rates

Sales Growth

3Y—

5Y—

10Y—

Profit Growth

3Y—

5Y—

10Y—

EPS Growth

3Y—

5Y—

10Y—

Peer Comparison

Healthcare

Stock	Price	Fair Value	MoS%	P/E	ROE	Signal
AHCL Anlon Healthcare Limited	₹13.9	₹50.7	+72.6%	20.5	7.3%	UNDERVALUED
ALPA Alpa Laboratories Limited	₹69.8	₹196.4	+64.5%	12.8	13.4%	FAIRLY_VALUED
ASTERDM Aster DM Healthcare	₹755.4	₹1,585.8	+52.4%	117.6	7.9%	UNDERVALUED
VIMTALABS Vimta Labs Limited	₹453	₹722.6	+37.3%	26.2	18.6%	UNDERVALUED
UNICHEMLAB Unichem Laboratories Limited	₹372.6	₹592.5	+37.1%	8.9	12.1%	FAIRLY_VALUED
DCAL Dishman Carbogen Amcis Limited	₹195.5	₹281.2	+30.5%	25.6	1.9%	FAIRLY_VALUED
INDRAMEDCO Indraprastha Medical Corporation Limited	₹358.2	₹462.6	+22.6%	18.5	20.6%	UNDERVALUED
MOREPENLAB Morepen Laboratories Limited	₹43	₹52.8	+18.5%	23.3	10.8%	FAIRLY_VALUED

Institutional Activity

Bulk deals, block deals, short selling & delivery volume — NSE data

Insider Trading

Community Pulse

What is Dalal Street saying?

r/IndiaInvestments · r/Dalal_Street_Investments · r/IndianStockMarket

No Reddit mentions found yet for ALIVUS.

StockTwits

What traders are saying right now

StockTwits

No StockTwits activity found for ALIVUS.

Search Interest

Google Trends · India · Last 90 days

Trends

Trend data not yet available — check back soon.

Telegram Channels

ET Markets · CNBC TV18 · Moneycontrol · Zee Business · NDTV Profit

No Telegram mentions found yet for ALIVUS.

Exchange Filings

BSE announcements · last 90 days

NSE ↗BSE ↗

Loading filings…

Share this Stock

Download card · Share on WhatsApp

Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant